Floatz logo

RAMIPRIL

Cardiotoxicity

Azienda Ospedaliero-Universitaria CareggiSmall moleculePhase 3Dormant
B
56/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
43/ 100
Competitive Position
81/ 100

Competitive context

14 Active assets in the Cardiotoxicity cohort.

Asset / SponsorPhaseRating
POTASSIUM
Tufts Medical Center
Phase 3BB
Orlistat
University of British Columbia
Phase 4BB
Acoramidis
Eidos Therapeutics, a BridgeBio company
Phase 3BB
CARVEDILOL
Abramson Cancer Center at Penn Medicine
Phase 3BB
Calcium
Phase 3BB

View all 36 →

Same molecule, other indications

RAMIPRIL is also rated in:

hypertensive disorderDormant
BBB
Indicative ·
73 / 100
View asset →
iatrogenicDormant
BB
Indicative ·
64 / 100
View asset →
coronary atherosclerosisDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →